CREATION OF ABIVAX – A LEADER IN THERAPEUTIC VACCINES AND THE FIRST FRENCH COMPANY TO SIGN AN EXCLUSIVE PARTNERING AGREEMENT WITH CUBA IN HEALTHCARE

Truffle Capital has announced the creation of Paris-based ABIVAX in collaboration with the Cuban Center for Genetic Engineering and Biotechnology (Centro de Ingenieria Genética y Biotecnologia, CIGB). This is the first ever start-up launched on the basis of a Euro-Cuban R&D collaboration. The goal of ABIVAX is to become a global leader in therapeutic vaccines and antivirals, leveraging both its existing product pipelines and future acquisitions that are currently in negotiations.

Press contacts

Caroline Carmagnol 

abivax@alizerp.com

+ 33 6 64 18 99 59 or
+ 33 1 44 54 36 65

 Standard: +33 1 53 83 08 41